{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04663347",
            "orgStudyIdInfo": {
                "id": "GCT3013-02"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-000845-15",
                    "type": "EUDRACT_NUMBER"
                },
                {
                    "id": "NL74222.056.20",
                    "type": "REGISTRY",
                    "domain": "CCMO"
                },
                {
                    "id": "283235",
                    "type": "OTHER",
                    "domain": "IRAS ID; UK Research Summaries Database"
                },
                {
                    "id": "2023-504805-35-00",
                    "type": "CTIS"
                }
            ],
            "organization": {
                "fullName": "Genmab",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)",
            "officialTitle": "A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody\u00ae-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)",
            "acronym": "EPCORE\u2122 NHL-2",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "safety-and-efficacy-trial-of-epcoritamab-combinations-in-subjects-with-b-cell-non-hodgkin-lymphoma-b-nhl"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true,
                "nctId": "NCT05733650",
                "statusForNctId": "APPROVED_FOR_MARKETING"
            },
            "startDateStruct": {
                "date": "2020-11-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-10-27",
            "studyFirstSubmitQcDate": "2020-12-04",
            "studyFirstPostDateStruct": {
                "date": "2020-12-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Genmab",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "AbbVie",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY\u2122), either by itself or together with other therapies, when treating subjects with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied.\n\nTrial details include:\n\n* The total trial duration will be up to 6 years.\n* The treatment duration for each participant depends upon which arm of treatment they are assigned to receive, but will be no more than 3 years.\n* The visit frequency for each participant depends upon which arm of treatment they are assigned to receive, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks.\n* All participants will receive active drug; no one will be given placebo.\n\nParticipants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned.\n\nParticipants who receive standard treatments will have IV infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.\n\nArm 9 (follicular lymphoma (FL)) is still open for enrolment of new patients, while the other arms have closed their recruitment.",
            "detailedDescription": "A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in participants with B-NHL.\n\nAll participants in the trial will receive epcoritamab, as monotherapy or in combination. The following regimens will be investigated:\n\n* Arm 1: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with previously untreated diffuse large B-cell lymphoma (DLBCL)\n* Arm 2: epcoritamab + rituximab and lenalidomide (R2) in participants with relapsed/refractory (R/R) FL\n* Arm 3: epcoritamab + rituximab and bendamustine (BR) in participants with previously untreated FL\n* Arm 4: epcoritamab + rituximab, cytarabine, dexamethasone, and oxaliplatin/ carboplatin (R-DHAX/C) in participants with R/R DLBCL eligible for autologous stem cell transplant (ASCT)\n* Arm 5: epcoritamab + gemcitabine and oxaliplatin (GemOx) in participants with R/R DLBCL ineligible for ASCT due to age, performance status (PS), or comorbidity\n* Arm 6: epcoritamab + R2 in participants with previously untreated FL\n* Arm 7: epcoritamab maintenance in participants with FL who achieve a complete response (CR) or a partial response (PR) with SOC treatment\n* Arm 8: epcoritamab + reduced dose of R-CHOP (R mini-CHOP) in participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline\n* Arm 9: epcoritamab + lenalidomide for second-line treatment in participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy\n* Arm 10: epcoritamab + rituximab, ifosfamide, carboplatin, and etoposide phosphate (R-ICE) in participants with R/R DLBCL eligible for ASCT\n\nThe trial consists of two parts: Part 1 ('Dose Escalation') and Part 2 ('Dose Expansion'). The primary objective of Part 1 is safety, and it includes Arm 1-5 and Arm 10. Part 2 includes all 10 arms (Arm 1-10) and the primary goal of all arms, except Arm 7, is preliminary efficacy. For Arm 7, the primary goal is safety. Patients in Arm 1-5 and Arm 10 can only participate in either Part 1 or Part 2. Dose Limiting Toxicities (DLTs) will be assessed in Part 1 and for a selected number of patients in Arm 8 during a 28-day period ('safety-run phase'). The arms are conducted in parallel."
        },
        "conditionsModule": {
            "conditions": [
                "Diffuse Large B-Cell Lymphoma",
                "Follicular Lymphoma"
            ],
            "keywords": [
                "DuoBody\u00ae",
                "monoclonal antibodies",
                "anti-CD3",
                "anti-CD20"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 662,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1 - Epcoritamab + R-CHOP",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with previously untreated DLBCL.",
                    "interventionNames": [
                        "Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 2 - Epcoritamab + R2",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with R/R FL.",
                    "interventionNames": [
                        "Drug: rituximab and lenalidomide",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 3 - Epcoritamab + BR",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with previously untreated FL.",
                    "interventionNames": [
                        "Drug: rituximab and bendamustine",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 4 - Epcoritamab + R-DHAX/C",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with R/R DLBCL eligible for ASCT.",
                    "interventionNames": [
                        "Drug: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 5 - Epcoritamab + GemOx",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with R/R DLBCL ineligible ASCT.",
                    "interventionNames": [
                        "Drug: gemcitabine and oxaliplatin",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 6 - Epcoritamab + R2",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with previously untreated FL.",
                    "interventionNames": [
                        "Drug: rituximab and lenalidomide",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 7 - Epcoritamab maintenance",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L.",
                    "interventionNames": [
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 8 - Epcoritamab + R mini-CHOP",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline.",
                    "interventionNames": [
                        "Drug: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 9 - Epcoritamab + Lenalidomide",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy.",
                    "interventionNames": [
                        "Drug: Lenalidomide",
                        "Biological: Epcoritamab"
                    ]
                },
                {
                    "label": "Arm 10 - Epcoritamab + R-ICE",
                    "type": "EXPERIMENTAL",
                    "description": "In participants with R/R DLBCL eligible for ASCT.",
                    "interventionNames": [
                        "Drug: rituximab, ifosfamide, carboplatin, and etoposide phosphate",
                        "Biological: Epcoritamab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone",
                    "description": "21-day cycles",
                    "armGroupLabels": [
                        "Arm 1 - Epcoritamab + R-CHOP"
                    ],
                    "otherNames": [
                        "R-CHOP"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "rituximab and lenalidomide",
                    "description": "28-day cycles",
                    "armGroupLabels": [
                        "Arm 2 - Epcoritamab + R2",
                        "Arm 6 - Epcoritamab + R2"
                    ],
                    "otherNames": [
                        "R2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "rituximab and bendamustine",
                    "description": "28-day cycles",
                    "armGroupLabels": [
                        "Arm 3 - Epcoritamab + BR"
                    ],
                    "otherNames": [
                        "BR"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin",
                    "description": "21-day cycles",
                    "armGroupLabels": [
                        "Arm 4 - Epcoritamab + R-DHAX/C"
                    ],
                    "otherNames": [
                        "R-DHAX/C"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "gemcitabine and oxaliplatin",
                    "description": "28-day cycles",
                    "armGroupLabels": [
                        "Arm 5 - Epcoritamab + GemOx"
                    ],
                    "otherNames": [
                        "GemOx"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.",
                    "armGroupLabels": [
                        "Arm 1 - Epcoritamab + R-CHOP"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone",
                    "description": "21-day cycles",
                    "armGroupLabels": [
                        "Arm 8 - Epcoritamab + R mini-CHOP"
                    ],
                    "otherNames": [
                        "R mini-CHOP"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lenalidomide",
                    "description": "28-day cycles",
                    "armGroupLabels": [
                        "Arm 9 - Epcoritamab + Lenalidomide"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "rituximab, ifosfamide, carboplatin, and etoposide phosphate",
                    "description": "21-day cycles",
                    "armGroupLabels": [
                        "Arm 10 - Epcoritamab + R-ICE"
                    ],
                    "otherNames": [
                        "R-ICE"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.",
                    "armGroupLabels": [
                        "Arm 2 - Epcoritamab + R2",
                        "Arm 3 - Epcoritamab + BR"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.",
                    "armGroupLabels": [
                        "Arm 4 - Epcoritamab + R-DHAX/C",
                        "Arm 5 - Epcoritamab + GemOx"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.",
                    "armGroupLabels": [
                        "Arm 6 - Epcoritamab + R2"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycle 1 and then every 8 weeks for a total of 2 years.",
                    "armGroupLabels": [
                        "Arm 7 - Epcoritamab maintenance"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.",
                    "armGroupLabels": [
                        "Arm 8 - Epcoritamab + R mini-CHOP"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.",
                    "armGroupLabels": [
                        "Arm 9 - Epcoritamab + Lenalidomide"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Epcoritamab",
                    "description": "Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.",
                    "armGroupLabels": [
                        "Arm 10 - Epcoritamab + R-ICE"
                    ],
                    "otherNames": [
                        "GEN3013",
                        "DuoBody\u00ae-CD3xCD20",
                        "EPKINLY\u2122"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants With Dose limiting Toxicities (DLTs)",
                    "description": "DLT events are defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0.",
                    "timeFrame": "During the first cycle (Cycle length= 28 days) in each cohort"
                },
                {
                    "measure": "Part 1 and Part 2 (Arm 7): Number of Participants With Adverse Events (AEs)",
                    "description": "An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.",
                    "timeFrame": "From first dose of trial medication to the maximum of 60 days after last dose of epcoritamab or initiation of subsequent anti-lymphoma therapy."
                },
                {
                    "measure": "Part 2 (Except Arm 7): Overall Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on Lugano criteria.",
                    "timeFrame": "Up to 3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1 and 2: Clearance (CL) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Volume of Distribution (Vd) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time Zero to Last Quantifiable Dose (AUC0-last) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time Zero to Infinity (AUC0-inf) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Maximum (Peak) Plasma Concentration (Cmax) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Time to Reach Cmax (Tmax) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Terminal Elimination Half-Life (t 1/2) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Plasma Trough (Pre-dose) Concentrations (Ctrough) of Epcoritamab",
                    "timeFrame": "Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)"
                },
                {
                    "measure": "Part 1 and 2: Number of Immune Cell Populations",
                    "description": "Immune cell populations in peripheral blood and tumor biopsies will be assessed.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Part 1 and 2: Percentage of Immune Cell Populations",
                    "description": "Immune cell populations in peripheral blood and tumor biopsies will be assessed.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Part 1 and 2: Change From Baseline in Cytokine Levels up to Cycle 3",
                    "description": "Change in cytokine levels in peripheral blood samples will be assessed.",
                    "timeFrame": "Up to Cycle 3 (cycle length = 21 days for Arms 1, 4, 8 and 10; cycle length = 28 days for Arms 2, 3, 5, 6 and 9; cycle length = 28 days (Cycle 1) and 56 days (Cycles 2, 3) for Arm 7)"
                },
                {
                    "measure": "Part 1 and 2: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (DNA) Level up to End of Treatment (up to 2 Years)",
                    "description": "Change in circulating tumor DNA levels will be assessed.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Part 1 and 2: Number of Participants With Anti-Drug Antibodies (ADAs) to Epcoritamab",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1: ORR",
                    "description": "ORR is defined as the percentage of participants achieving CR or PR based on Lugano criteria.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Duration of Response (DOR)",
                    "description": "DOR: the time from the first documentation of objective tumor response (CR or PR) to the date of first PD or death based on Lugano criteria.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Time to Response (TTR)",
                    "description": "TTR is defined as the time from Day 1 of Cycle 1 to first documentation of objective tumor response (CR or PR).",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause based on Lugano criteria.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Overall Survival (OS)",
                    "description": "OS is defined as the time from the date of first dose, to the date of death due to any cause.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Time to Next Anti-lymphoma Therapy (TTNT)",
                    "description": "TTNT is defined as the time from Day 1 of Cycle 1 to first documented administration of subsequent anti-lymphoma therapy.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Percentage of Participants With Minimal Residual Disease (MRD) Negativity",
                    "description": "It is defined as the percentage of participants with at least 1 MRD negative result.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Duration of minimal residual disease (MRD) negativity",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 2 (Arm 7): Percentage of Participants Who Converted From MRD Positivity to MRD Negativity",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 2 (Except Arm 7): Percentage of Participants with Complete Response (CR) in Arms 1 to 10",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 2 (Arm 7): Percentage of Participants With CR",
                    "description": "It is defined as the percentage of participants who remain in complete remission or converting to complete remission after first trial drug administration.",
                    "timeFrame": "Week 24, Week 48, and Week 96"
                },
                {
                    "measure": "Part 1 and 2: Time to Complete Response (TTCR)",
                    "description": "TTCR is defined as the time from first trial drug administration to the date of first documented complete response post-treatment.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Part 1 and 2: Duration of Complete Response (DoCR)",
                    "description": "DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs first based on Lugano criteria.",
                    "timeFrame": "Up to 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria\n\n1. Measurable disease defined as \u22651 measurable nodal lesion (long axis \\>1.5 cm and short axis \\>1.0 cm) or \u22651 measurable extra-nodal lesion (long axis \\>1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI)\n2. Eastern Cooperative Oncology Group (ECOG) PS score of 0, 1 or 2\n3. Acceptable organ function at screening\n4. CD20-positive non-Hodgkin lymphoma (NHL) at most recent representative tumor biopsy\n5. If of childbearing potential subject must practicing a highly effective method of birth control\n6. A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control\n\nArm 1:\n\n* Newly diagnosed DLBCL\n* DLBCL, not otherwise specified (NOS)\n* \"Double-hit\" or \"triple-hit\" DLBCL\n* FL Grade 3B\n\nArm 2: R/R FL\n\nArm 3: Newly diagnosed, previously untreated FL grade 1-3A\n\nArm 4:\n\n* Documented R/R DLBCL and eligible for HDT-ASCT\n* DLBCL, NOS\n* \"Double-hit\" or \"triple-hit\" DLBCL\n* FL Grade 3B\n\nArm 5:\n\n* Documented R/R DLBCL and ineligible for HDT-ASCT\n* DLBCL, NOS\n* \"Double-hit\" or \"triple-hit\" DLBCL\n* FL Grade 3B\n\nArm 6: Newly diagnosed, previously untreated FL grade 1-3A\n\nArm 7:\n\n* FL Grade 1-3A\n* If PR or CR per Lugano criteria following first-line or second-line treatment with SOC regimen, and last dose of SOC within 6 months prior to enrollment.\n\nArm 8:\n\n* Newly diagnosed DLBCL who are not fit to receive full-dose anthracycline\n* T-cell/histiocyte rich DLBCL\n* \"Double-hit\" or \"triple-hit\" DLBCL\n* FL Grade 3B\n\nArm 9:\n\n* R/R FL\n* Progressed within 24 months of initiating first-line treatment\n\nArm 10:\n\n* Documented R/R DLBCL and eligible for HDT-ASCT\n* DLBCL, NOS\n* \"Double-hit\" or \"triple-hit\" DLBCL\n* FL Grade 3B\n\nKey Exclusion Criteria\n\n1. Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first dose of epcoritamab\n2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.\n3. Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab\n4. Clinically significant cardiovascular disease\n5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results\n6. CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT scan of the brain and, if clinically indicated, by lumbar puncture\n7. Positive tests for hepatitis B virus or hepatitis C virus indicating acute or chronic infection\n8. Known history of seropositivity of human immunodeficiency virus (HIV)\n9. Active tuberculosis or history of completed treatment for active tuberculosis within the past 12 months\n10. Neuropathy \\> grade 1\n11. Receiving immunostimulatory agent\n12. Prior allogeneic HSCT\n13. Current seizure disorder requiring anti-epileptic therapy\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Genmab A/S Trial Information",
                    "role": "CONTACT",
                    "phone": "+45 70202728",
                    "email": "clinicaltrials@genmab.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Cedars-Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "David Geffen School of Medicine at UCLA",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "University of Michigan Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "84109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "John Theurer Cancer Center at Hackensack UMC",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering CC",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Levine Cancer Center",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "UMPC Hillman Cancer Center Cancer Pavillion",
                    "status": "WITHDRAWN",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "UT Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Monash Medical Centre",
                    "status": "COMPLETED",
                    "city": "Clayton",
                    "state": "Victoria",
                    "zip": "3084",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                },
                {
                    "facility": "Austin Health",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "zip": "VIC 3084",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.75,
                        "lon": 145.06667
                    }
                },
                {
                    "facility": "Linear Clinical Research Limited",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "AZ Sint-Jan",
                    "status": "RECRUITING",
                    "city": "Brugge",
                    "zip": "8000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.20892,
                        "lon": 3.22424
                    }
                },
                {
                    "facility": "Universitair Ziekenhuis Gent",
                    "status": "RECRUITING",
                    "city": "Gent",
                    "zip": "9000",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.05,
                        "lon": 3.71667
                    }
                },
                {
                    "facility": "CHU UCL Namur Site Godinne",
                    "status": "RECRUITING",
                    "city": "Yvoir",
                    "zip": "5530",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 50.3279,
                        "lon": 4.88059
                    }
                },
                {
                    "facility": "Fakultni nemocnice Hradec Kralove",
                    "status": "RECRUITING",
                    "city": "Hradec Kr\u00e1lov\u00e9",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 50.20923,
                        "lon": 15.83277
                    }
                },
                {
                    "facility": "Fakultni nemocnice Ostrava",
                    "status": "RECRUITING",
                    "city": "Ostrava - Poruba",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 49.83465,
                        "lon": 18.28204
                    }
                },
                {
                    "facility": "Fakultni nemocnice v Motole",
                    "status": "RECRUITING",
                    "city": "Prague",
                    "zip": "15006",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 50.08804,
                        "lon": 14.42076
                    }
                },
                {
                    "facility": "Vseobecna Fakultni Nemocnice",
                    "status": "RECRUITING",
                    "city": "Praha 2",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 50.08804,
                        "lon": 14.42076
                    }
                },
                {
                    "facility": "\u00c5rhus Hospital",
                    "status": "RECRUITING",
                    "city": "Arhus",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 56.15674,
                        "lon": 10.21076
                    }
                },
                {
                    "facility": "Rigshospitalet",
                    "status": "RECRUITING",
                    "city": "Copenhagen",
                    "zip": "2100",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.67594,
                        "lon": 12.56553
                    }
                },
                {
                    "facility": "Odense University Hospital",
                    "status": "RECRUITING",
                    "city": "Odense",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.39594,
                        "lon": 10.38831
                    }
                },
                {
                    "facility": "Vejle Sygehus",
                    "status": "RECRUITING",
                    "city": "Vejle",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.70927,
                        "lon": 9.5357
                    }
                },
                {
                    "facility": "Tampere University Hospital",
                    "status": "RECRUITING",
                    "city": "Helsinki",
                    "zip": "33520",
                    "country": "Finland",
                    "geoPoint": {
                        "lat": 60.16952,
                        "lon": 24.93545
                    }
                },
                {
                    "facility": "Kuopio University Hospital",
                    "status": "RECRUITING",
                    "city": "Kuopio",
                    "zip": "70210",
                    "country": "Finland",
                    "geoPoint": {
                        "lat": 62.89238,
                        "lon": 27.67703
                    }
                },
                {
                    "facility": "HUS Cancer Center",
                    "status": "RECRUITING",
                    "city": "Lahti",
                    "zip": "15850",
                    "country": "Finland",
                    "geoPoint": {
                        "lat": 60.98267,
                        "lon": 25.66151
                    }
                },
                {
                    "facility": "Institut Bergoni\u00e9",
                    "status": "RECRUITING",
                    "city": "Bordeaux",
                    "zip": "33076",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "CHU Dijon - Hopital du Bocage",
                    "status": "RECRUITING",
                    "city": "Dijon",
                    "zip": "21000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.31667,
                        "lon": 5.01667
                    }
                },
                {
                    "facility": "Hopital Claude Huriez - CHRU Lille",
                    "status": "RECRUITING",
                    "city": "Lille",
                    "zip": "59037",
                    "country": "France",
                    "geoPoint": {
                        "lat": 50.63297,
                        "lon": 3.05858
                    }
                },
                {
                    "facility": "H\u00f4pital de la Timone",
                    "status": "RECRUITING",
                    "city": "Marseille",
                    "zip": "13005",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.29551,
                        "lon": 5.38958
                    }
                },
                {
                    "facility": "H\u00f4pital Saint-Louis",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75475",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Centre Hospitalier Lyon Sud",
                    "status": "RECRUITING",
                    "city": "Pierre-B\u00e9nite",
                    "zip": "69495",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.7009,
                        "lon": 4.82511
                    }
                },
                {
                    "facility": "Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)",
                    "status": "RECRUITING",
                    "city": "Bergamo",
                    "zip": "24127",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.69601,
                        "lon": 9.66721
                    }
                },
                {
                    "facility": "Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS",
                    "status": "RECRUITING",
                    "city": "Candiolo",
                    "zip": "10060",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.95858,
                        "lon": 7.59812
                    }
                },
                {
                    "facility": "Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori",
                    "status": "RECRUITING",
                    "city": "Meldola",
                    "zip": "47014",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.12775,
                        "lon": 12.0626
                    }
                },
                {
                    "facility": "Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico",
                    "status": "RECRUITING",
                    "city": "Milan",
                    "zip": "20122",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Fondazione IRCCS Policlinico San Matteo",
                    "status": "RECRUITING",
                    "city": "Pavia",
                    "zip": "27100",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.19205,
                        "lon": 9.15917
                    }
                },
                {
                    "facility": "Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia",
                    "status": "RECRUITING",
                    "city": "Reggio Emilia",
                    "zip": "42123",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.69825,
                        "lon": 10.63125
                    }
                },
                {
                    "facility": "Amsterdam UMC, Locatie VUMC",
                    "status": "RECRUITING",
                    "city": "Amsterdam",
                    "zip": "1105 AZ",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "Universitair Medisch Centrum Groningen (UMCG)",
                    "status": "RECRUITING",
                    "city": "Groningen",
                    "zip": "9713",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 53.21917,
                        "lon": 6.56667
                    }
                },
                {
                    "facility": "Leids Universitair Medisch Centrum",
                    "status": "RECRUITING",
                    "city": "Leiden",
                    "zip": "2333 ZA",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.15833,
                        "lon": 4.49306
                    }
                },
                {
                    "facility": "Maastricht University Medical Center",
                    "status": "RECRUITING",
                    "city": "Maastricht",
                    "zip": "6229 HX",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 50.84833,
                        "lon": 5.68889
                    }
                },
                {
                    "facility": "Erasmus Medisch Centrum",
                    "status": "RECRUITING",
                    "city": "Rotterdam",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.9225,
                        "lon": 4.47917
                    }
                },
                {
                    "facility": "UMC Utrecht",
                    "status": "RECRUITING",
                    "city": "Utrecht",
                    "zip": "3584",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.09083,
                        "lon": 5.12222
                    }
                },
                {
                    "facility": "Oslo Universitetssykehus HF, Radiumhospitalet",
                    "status": "RECRUITING",
                    "city": "Oslo",
                    "zip": "310",
                    "country": "Norway",
                    "geoPoint": {
                        "lat": 59.91273,
                        "lon": 10.74609
                    }
                },
                {
                    "facility": "ICO l Hospitalet",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08908",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitari Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "8035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario La Paz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28046",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario de Salamanca",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                },
                {
                    "facility": "S\u00f6dra \u00c4lvsborgs Sjukhus",
                    "status": "RECRUITING",
                    "city": "Bor\u00e5s",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 57.72101,
                        "lon": 12.9401
                    }
                },
                {
                    "facility": "Sahlgrenska Sjukhuset",
                    "status": "RECRUITING",
                    "city": "G\u00f6teborg",
                    "zip": "413 45",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 57.70716,
                        "lon": 11.96679
                    }
                },
                {
                    "facility": "Sk\u00e5nes Universitetssjukhus",
                    "status": "RECRUITING",
                    "city": "Lund",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 55.70584,
                        "lon": 13.19321
                    }
                },
                {
                    "facility": "Karolinska Universitetssjukhuset",
                    "status": "RECRUITING",
                    "city": "Solna",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 59.36004,
                        "lon": 18.00086
                    }
                },
                {
                    "facility": "Norrlands Universitetssjukhus",
                    "status": "RECRUITING",
                    "city": "Ume\u00e5",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 63.82842,
                        "lon": 20.25972
                    }
                },
                {
                    "facility": "Akademiska Sjukhuset",
                    "status": "RECRUITING",
                    "city": "Uppsala",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 59.85882,
                        "lon": 17.63889
                    }
                },
                {
                    "facility": "University College London Hospitals",
                    "status": "COMPLETED",
                    "city": "London",
                    "zip": "NW1 2PG",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "The Christie NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Manchester",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                },
                {
                    "facility": "Freeman Hospital",
                    "status": "RECRUITING",
                    "city": "Newcastle Upon Tyne",
                    "zip": "NE7 7D",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 54.97328,
                        "lon": -1.61396
                    }
                },
                {
                    "facility": "Derriford Hospital",
                    "status": "RECRUITING",
                    "city": "Plymouth",
                    "zip": "PL6 8DH",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 50.37153,
                        "lon": -4.14305
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Patient website: Recruiting clinical sites in Finland",
                    "url": "https://fimea.fi/valvonta/kliiniset_laaketutkimukset/rekrytoivat-tutkimukset"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                },
                {
                    "id": "D000016403",
                    "term": "Lymphoma, Large B-Cell, Diffuse"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18831",
                    "name": "Lymphoma, Large B-Cell, Diffuse",
                    "asFound": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11221",
                    "name": "Lymphoma, Follicular",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1866",
                    "name": "Diffuse Large B-Cell Lymphoma",
                    "asFound": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2361",
                    "name": "Follicular Lymphoma",
                    "asFound": "Follicular lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003561",
                    "term": "Cytarabine"
                },
                {
                    "id": "D000003907",
                    "term": "Dexamethasone"
                },
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069461",
                    "term": "Bendamustine Hydrochloride"
                },
                {
                    "id": "D000007069",
                    "term": "Ifosfamide"
                },
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "C000506643",
                    "term": "Liposomal doxorubicin"
                },
                {
                    "id": "D000077150",
                    "term": "Oxaliplatin"
                },
                {
                    "id": "D000005047",
                    "term": "Etoposide"
                },
                {
                    "id": "D000014750",
                    "term": "Vincristine"
                },
                {
                    "id": "D000077269",
                    "term": "Lenalidomide"
                },
                {
                    "id": "C000061400",
                    "term": "Etoposide phosphate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8191",
                    "name": "Etoposide",
                    "asFound": "Biceps",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10117",
                    "name": "Ifosfamide",
                    "asFound": "Ventricular",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17495",
                    "name": "Vincristine",
                    "asFound": "Phase I",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7102",
                    "name": "Dexamethasone",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M235549",
                    "name": "Dexamethasone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "asFound": "Min",
                    "relevance": "HIGH"
                },
                {
                    "id": "M430",
                    "name": "Bendamustine Hydrochloride",
                    "asFound": "Inserted",
                    "relevance": "HIGH"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1725",
                    "name": "Lenalidomide",
                    "asFound": "Respiratory",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6766",
                    "name": "Cytarabine",
                    "asFound": "Delivered",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M341643",
                    "name": "Etoposide phosphate",
                    "asFound": "Biceps",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19201",
                    "name": "Muromonab-CD3",
                    "relevance": "LOW"
                },
                {
                    "id": "M230811",
                    "name": "Isophosphamide mustard",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}